Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: maserati r. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
Carosi G, Puoti M, Antonucci G, De Luca A, Maserati R, Torti C, Bonfanti P, Bonora S, Bruno R, Gaeta GB, Antinori A, Monforte Ad, Orani A, Sagnelli E, Cargnel A, Cauda R, Mazzotta F, Pastore G, Suter F, Vullo V; Italian ART; HCV-HIV Coinfection Working Group. Carosi G, et al. Among authors: maserati r. AIDS Rev. 2005 Jul-Sep;7(3):161-7. AIDS Rev. 2005. PMID: 16302464
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: maserati r. J Antimicrob Chemother. 2007 Jun;59(6):1141-7. doi: 10.1093/jac/dkm100. Epub 2007 Apr 13. J Antimicrob Chemother. 2007. PMID: 17434879
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Prosperi MC, et al. J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. J Antimicrob Chemother. 2011. PMID: 21624929
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Gori A, Antinori A, Vergori A, Cossu MV, Menzaghi B, Sterrantino G, Rusconi S, Cattelan AM, Castelli F, Gianotti N, Orofino G, Ripamonti D, Savinelli S, Manzillo E, Santantonio TA, Celesia BM, Cauda R, Maserati R, d'Arminio Monforte A, Stingone C, Bonora S, Uglietti A, Termini R, Rucci F, Mancusi D. Gori A, et al. Among authors: maserati r. J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):290-294. doi: 10.1097/QAI.0000000000002331. J Acquir Immune Defic Syndr. 2020. PMID: 32101882 Free PMC article.
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Trabattoni D, Lo Caputo S, Biasin M, Seminari E, Di Pietro M, Ravasi G, Mazzotta F, Maserati R, Clerici M. Trabattoni D, et al. Among authors: maserati r. Clin Diagn Lab Immunol. 2002 Sep;9(5):1114-8. doi: 10.1128/cdli.9.5.1114-1118.2002. Clin Diagn Lab Immunol. 2002. PMID: 12204968 Free PMC article. Clinical Trial.
215 results